101 related articles for article (PubMed ID: 698922)
1. In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo.
Yuhas JM; Tarleton AE; Harman JG
Cancer Res; 1978 Nov; 38(11 Pt 1):3595-8. PubMed ID: 698922
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
3. Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival.
Begg AC; Fu KK; Kane LJ; Phillips TL
Cancer Res; 1980 Jan; 40(1):145-54. PubMed ID: 7349894
[No Abstract] [Full Text] [Related]
4. The response of EMT6 tumor spheroids to combined treatment with misonidazole and either nitrogen mustard, adriamycin, or BCNU.
Twentyman PR
Cancer Clin Trials; 1980; 3(3):253-6. PubMed ID: 7438322
[TBL] [Abstract][Full Text] [Related]
5. The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids.
Zwi LJ; Baguley BC; Gavin JB; Holdaway KM; Wilson WR
Oncol Res; 1992; 4(8-9):333-9. PubMed ID: 1486217
[TBL] [Abstract][Full Text] [Related]
6. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
7. Proliferative character and growth modes of neoplastic disease as determinants of chemotherapeutic efficacy.
Schenken LL
Cancer Treat Rep; 1976 Dec; 60(12):1761-76. PubMed ID: 829040
[No Abstract] [Full Text] [Related]
8. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
[No Abstract] [Full Text] [Related]
9. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
Frankel A; Buckman R; Kerbel RS
Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound triggered release of cisplatin from liposomes in murine tumors.
Schroeder A; Honen R; Turjeman K; Gabizon A; Kost J; Barenholz Y
J Control Release; 2009 Jul; 137(1):63-8. PubMed ID: 19303426
[TBL] [Abstract][Full Text] [Related]
13. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
Heppner GH; Dexter DL; DeNucci T; Miller FR; Calabresi P
Cancer Res; 1978 Nov; 38(11 Pt 1):3758-63. PubMed ID: 698935
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cytogenetic damage and of antineoplastic effect by caffeine in Ehrlich ascites tumor cells treated with cyclophosphamide in vivo.
Mourelatos D; Dozi-Vassiliades J; Kotsis A; Gourtsas C
Cancer Res; 1988 Mar; 48(5):1129-31. PubMed ID: 3342394
[TBL] [Abstract][Full Text] [Related]
17. Oxygen tensions in two human tumor cell lines grown and irradiated as multicellular spheroids.
Schwachöfer JH; Acker H; Crooijmans RP; Van Gasteren JJ; Holtermann G; Hoogenhout J; Jerusalem CR; Kal HB
Anticancer Res; 1991; 11(1):273-9. PubMed ID: 2018361
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL; Zou WY; Song LH; Wei W
Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of MOPC 104E myeloma in plateau phase.
Ghanta VK; Hiramoto RN; Davis DW; Hiramoto NS
Cancer Res; 1980 Jul; 40(7):2372-6. PubMed ID: 7190063
[TBL] [Abstract][Full Text] [Related]
20. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
